weight loss drugs
Search documents
Health equity expert calls Trump’s school fitness test plan ‘political theater’
MSNBC· 2025-08-03 17:33
Health & Policy - The discussion revolves around President Trump's executive order to reinstate the presidential fitness test in public schools, initially established in 1956 by President Eisenhower [1] - The policy is viewed as performative and political theater, unlikely to address childhood obesity effectively [4] - The core issue lies in structural problems such as limited access to healthy food, a flawed healthcare system, unsafe neighborhoods for exercise, and insufficient recess or physical education [5][6] - Michelle Obama's "Let's Move" campaign, aimed at promoting physical activity and healthy school lunches, faced ridicule from conservatives, highlighting potential political motivations behind health initiatives [10][11] Obesity & Treatment - Over 70% of children and 85% of teenagers do not meet the 2024 federal minimum recommendation for daily moderate to vigorous physical activity, with higher rates among children of color [3] - The administration plans to experiment with Medicare and Medicaid coverage for weight loss drugs like Ozempic and Wegovy, addressing disparities in obesity treatment access [13] - While medication is beneficial, it's not a complete solution; preventive and wraparound services are essential, raising concerns about Medicaid cuts affecting state affordability of GLP-1s [14][15] Nutrition & Systemic Issues - The administration's focus on changing ingredients in junk food is seen as addressing issues on a granular level rather than tackling systemic problems [17][18] - Addressing the underinsured and uninsured populations, predominantly people of color, is crucial for ensuring access to preventive care and resolving systemic issues impacting communities [19]
X @Bloomberg
Bloomberg· 2025-07-30 17:04
Company Transformation - Novo Nordisk's weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant [1] Market Value - Four years after Wegovy's US launch, the Danish drugmaker's market value has plummeted [1]